Economic Evaluation of Ilaprazole Injection in Patients with Peptic Ulcer Bleeding and Low-Risk Stigmata
10.3870/j.issn.1004-0781.2025.05.014
- VernacularTitle:注射用艾普拉唑治疗消化性溃疡出血低危患者的药物经济学评价
- Author:
Tingting LI
1
;
He ZHU
;
Lina ZHAO
;
Xu SUN
;
Fenli SU
;
Fen XIONG
;
Hongmei TANG
Author Information
1. 广州中医药大学第一附属医院药学部,广州 510405;广东省中医临床研究院,广州 510405
- Publication Type:Journal Article
- Keywords:
Ilaprazole;
Omeprazole;
Peptic ulcer bleeding;
Decision tree model;
Pharmacoeconomics;
Cost minimization analysis
- From:
Herald of Medicine
2025;44(5):758-763
- CountryChina
- Language:Chinese
-
Abstract:
Objective To perform an economic evaluation of ilaprazole in the treatment of patients with peptic ulcer bleeding and low-risk stigmata,and to provide a reference for drug selection.Methods From a societal perspective,we used decision analysis to evaluate the cost and effectiveness of ilaprazole and omeprazole in treating peptic ulcer bleeding patients dur-ing hospital stays.The probabilities of model nodes were taken from phase Ⅲ clinical trial research results,while cost data came from national medical insurance prices,published literature,and hospital databases.Sensitivity analysis and scenario analysis were performed to test the stability of the results.Results A cost minimization analysis was performed.Under the basic setting,the cost of the ilaprazole group was 4 038.99 yuan,and that of the omeprazole group was 3 837.61 yuan,which means that the cost of the ilaprazole group was 201.38 yuan higher.Sensitivity analysis showed that the results were stable.Scenario analysis showed that ilaprazole was more cost-effective than the innovator drug of omeprazole.Conclusion Ilaprazole was less economical than ome-prazole in the treatment of peptic ulcer bleeding patients with low-risk stigmata.
